/
MAZE
$28.95+$0.52 (+1.83%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.6B
55M shares
52-week range
$10.98 – $53.65
42% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.54%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$13.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $167.5M | $0 |
| Cost of revenue | $0 | $0 | $0 | $2.4M |
| Gross profit | $0 | $0 | $167.5M | −$2.4M |
| Gross margin | — | — | 100.0% | — |
| R&D | $88.2M | $73.9M | $83.5M | $108.4M |
| Operating income | −$111.0M | −$98.6M | $57.6M | −$142.9M |
| EBITDA | −$111.1M | −$96.3M | $56.7M | −$128.7M |
| Net income | −$114.9M | −$100.4M | $52.2M | −$131.1M |
| Net margin | — | — | 31.2% | — |
| EPS (diluted) | -2.63 | -2.29 | 0.08 | -3.05 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $22M | $-2.73 | $-3.10–$-2.00 | 7 |
| 2027 | $14M | $-3.22 | $-4.50–$-2.27 | 7 |
| 2028 | $11M | $-3.64 | $-5.93–$-2.74 | 6 |
| 2029 | $51M | $-3.86 | $-3.86–$-3.86 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.82
Price
$28.95
Implied downside
-87%
Peer comparison
Maze Therapeutics, Inc. Common Stock
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
www.mazetx.com- Employees
- 141
- IPO / List date
- Jan 31, 2025
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds MAZE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 15,800 | $471.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MAZE yet.
